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*1489 RESPECTING, RATHER THAN REACTING TO, RACE IN BASIC BIOMEDICAL 
RESEARCH: A RESPONSE TO PROFESSORS CAULFIELD AND MWARIA 
 
Michael J. Malinowski [FNa1] 
 
Copyright © 2009 Houston Law Review; Michael J. Malinowski 
 
I step back into this Article and the surrounding debate just weeks after a return trip to 
Taipei, Taiwan and Academia Sinica (AS), the Taiwan government's research arm. [FN1] 
While I was hosted by Institutum Jurisprudentia (AS's law institute) on this trip, [FN2] I 
also had an opportunity to spend time with one of my former hosts and to catch up on 
the progress of the Taiwan Biobank ("TBio")--a project that I was introduced to in August 
2007. [FN3] The plan for TBio is to collect 15,000 blood samples from the Chiayi, 
Hualien, and Miaoli counties and to cover the country's four core ethnic groups--Minnan, 
Hakka, Han immigrants who moved to Taiwan after 1949, and indigenous peoples. [FN4] 
Though well funded, the project was stalled for several years before my first visit and 
*1490 has been since due to concerns over privacy, confidentiality, and fair usage of 
information. [FN5] Still, AS researchers have been building and using the TBio internally; 
it has enabled their faculty to enter into collaborations with the organizers of other 
biobanks, and they have generated significant science results. The most recent is a 
sophisticated, race-sensitive reference algorithm for Warfarin, an anticoagulant used to 
prevent heart attacks, strokes, and blood clots. This accomplishment is the subject of a 
forthcoming article that will appear in the February 19, 2009 issue of the New England 
Journal of Medicine. [FN6] Previously, the team identified a gene that exists only in South 
Asian populations that is associated with Stevens-Johnson Syndrome, an adverse drug 
reaction that causes skin devastation and is potentially fatal. [FN7] TBio is one 
illustration: race and ethnicity-based genetics research are making human health 
contributions and benefiting the groups under study. 
I accepted the Houston Law Review's invitation to publish my article, Dealing with the 
Realities of Race and Ethnicity: A Bioethics-Centered Argument in Favor of Race-Based 
Genetics Research, [FN8] on the condition that we solicited responses from colleagues 
who disagree. [FN9] The goal was to maximize the contribution to the surrounding 
debate--to jolt it forward to the fullest extent possible. I embrace this opportunity to 
highlight and clarify a few core points in Dealing and, more generally, to engage in this 
dialogue with Professors Caulfield and Mwaria. 
Professors Caulfield and Mwaria both emphasize the importance of definitional precision. 
[FN10] In fact, that is the core of *1491 Professor Caulfield's comments, which I 
generally accept and incorporate by reference. I did not embark upon a discussion of 
definitional conviction directly in Dealing largely because the context focus is human 
subject recruitment for basic ("bench") research in population genetics--a stage generally 
preliminary to media reporting on discoveries, biopharmaceutical marketing, and 
prescribing of derived human health products. My focus was on communicating with 
subjects-- respect for how people self identify. The general thrust of the Article is to 
promote bench research in population genetics that will enable more meaningful 
definitional certainty, deepen understanding at the interface of genetics and environment, 
and improve human health. My use of "responsible research" throughout Dealing 
suggests care with definitions to the fullest extent practicable. [FN11] Moreover, the last 
sentence in my article before the conclusion, the closing statement, is "Fortunately, those 
who dare engage in race- and ethnicity-based research trigger suspicion and scrutiny that 
necessitates extreme clarity and precision to maintain credibility." [FN12] I continue to 
support recognition of and responsiveness to social and cultural definitions of race and 
ethnicity--how people actually relate and function--in subject recruitment to promote 
communication, reflection on group impact, and the informed consent process. 
Professor Caulfield observes, "[I]t is my impression that almost everyone, regardless of 
disciplinary background, recognizes the value of race as a research variable . . . ." [FN13] 
Not Professor Mwaria. She recognizes just one use, and it is outside of genetic science: 
"There is, however, one area [just one!] in which so-called race based medical research is 
valid. That is in research relating to access to health care or health care disparities." 
[FN14] 
*1492 While we are 99.9% the same genetically and generally homogenous as Professor 
Mwaria reminds us, the human health differences among us are immense, including our 
diverse responses to prescription medications. We use crude genetic classifications all the 
time, including many common disease classifications such as "breast cancer," [FN15] 
because genetics is so subtle, environment matters so much, and our science is still so 
limited. Medicine is an art, even guesswork, rather than predictable science. [FN16] 
As observed by Professor Pilar Ossorio,  
. . . there are legitimate reasons to use race as a variable in answering some research 
questions or in making some medical decisions. Race variables may generate data that 
point towards new medical interventions or cures, or towards better understandings of 
the causes of health problems. At times, race may be a proxy for some cause that we 
cannot yet measure or have not figured out that we should measure. Race variables may 
also be useful in assessing the effects of racism and institutional inequalities in access to 
health care or other health-promoting goods in society. Finally, race variables may 
capture aspects of a person's cumulative life experience, effects that are difficult or 
impossible to disaggregrate into separate variables; the same could be true for gender 
and class variables. [FN17] 
My appreciation to Professors Caulfiled and Mwaria for enriching this debate, and to the 
Houston Law Review. 
 
[FNa1]. Ernest R. and Iris M. Eldred Professor of Law, Paul M. Herbert Law Center, 
Louisiana State University. JD Yale Law School; BA, summa cum laude, Tufts University. 
 
[FN1]. For information about AS, visit their official internet site at 
http://www.sinica.edu.tw/main_e.shtml (last visited Feb. 6, 2009). 
 
[FN2]. The purpose of this trip was to give a keynote address at the 2nd Conference on 
Law, Science, and Technology, entitled "Science Regulation, Freedom of Research, and 
Pluralist Democracy," hosted by AS's Institutum Jurisprudentia, and to participate in a 
panel discussion at the National University of Taiwan. Michael J. Malinowski, Keynote 
Address at the 2nd Conference on Law, Science, and Technology: A Law-Policy Proposal 
to Promote the Public Nature of Science in an Era of Academia-Industry Integration, Dec. 
21, 2008 (written presentation on file with the author). 
 
[FN3]. I was invited by the National Genotyping Center to present at a public meeting to 
launch the Taiwan Biobank held in Taipei, Taiwan, August 12- 14, 2007. 
 
[FN4]. Sara Chuang, Dilemmas of Research, Taiwan Rev., Jan. 7, 2006, available at 
http://taiwanreview.nat.gov.tw/site/Tr/ct.asp? xItem=22901&ctNode=119 (last visited 
Feb. 6, 2009). 
 
[FN5]. Chia-Hao Ou & Chen-Yang Shen, The Taiwan Biobank Project: For the Health of 
Future Generation, E-news (Academia Sinica, Taipei, Taiwan), Apr. 19, 2007, available at 
http://newsletter.sinica.edu.tw/en/file/file/1/125.pdf (last visited Feb. 6, 2009). 
 
[FN6]. This latest discovery is part of a broader body of the team's work identifying 
ethnic differences in Warfarin sensitivity. See H.Y. Yuan, J.J. Chen, M.T. Lee, J.C. Wung, 
Y.F. Chen, M.J. Charng, M.J. Lu, C.R. Hung, C.Y. Wei, C.H. Chen, J.Y. Wu & Y.T. Chen, A 
Novel Functional VKORC1 Promoter Polymorphism Is Associated With Inter-Individual and 
Inter-Ethnic Differences in Warfarin Sensitivity, 14 Hum. Molecular Genetics 1745-51 
(2005). 
 
[FN7]. W.H. Chung, S.I. Hong, H.S. Hong, M.S. Hsih, L.C. Yang, H.C. Ho, J.Y. Wu & Y.T. 
Chen, Medical Genetics: A Marker for Stevens-Johnson Syndrome, 428 Nature 486 
(2004). 
 
[FN8]. Michael J. Malinowski, Dealing With the Realities of Race and Ethnicity: A 
Bioethics-Centered Argument in Favor of Race-Based Genetics Research, 45 Hous. L. 
Rev. 1415 (2009). 
 
[FN9]. I had anticipated more division between Professor Caulfield and I but, apparently, 
the evolution of our positions and the debate itself have drawn us closer together on this 
topic. 
 
[FN10]. See generally Timothy Caulfield, Defining Race as the Defining Problem, 45 Hous. 
L. Rev. 1475 (2009); Cheryl Mwaria, Rejecting Race as a Critical Marker of Human 
Biomedical Difference, 45 Hous. L. Rev. 1483 (2009). Professor Duster, a sociologist and 
leading critic of race and ethnicity-based genetics research, also demands definitional 
certainty, and I often agree with him on this point as well. See infra note 13 (quoting 
Professor Duster). See also Malinowski, supra note 8, at 1434-5 (summarizing Professor 
Duster's position). 
 
[FN11]. See, e.g., Malinowski, supra note 8, at 1421. There is danger of muddling 
communication between researchers and human subjects, perhaps chilling participation, 
through excessive definitional detail with too many layers of scientific terminology, 
especially at the bench-research level and in the population genetics context--the very 
beginning of the discovery process. 
 
[FN12]. Malinowski, supra note 8, at 1471. 
 
[FN13]. Caulfield, supra note 10, at 1476. 
 
[FN14]. Mwaria, supra note 10, at 1486. Consider that even Professor Duster, mentioned 
in supra note 10, has a broader vision. See generally Troy Duster, Race and Reification in 
Science, 307 Science 1050 (2008). Professor Duster recognizes that "The ability to use 
genomic knowledge to deliver effective pharmaceuticals more safely to special 
subpopulations that have some functional genetic markers holds promise." Id. at 1051. 
He demands definitional certainly as that becomes possible, as the science is done and 
alleles are identified, and a warning before:  
[W]hen the phenotype distinguishing these populations is race, the likelihood of 
committing the fallacy of misplaced concreteness, in science, is nearly overwhelming. For 
this reason, when geneticists report population data, they should always attach a caveat 
or warning label that could read something like this, "allelic frequencies vary between and 
selected human groups--to assume that those variations reflect 'racial categories' is 
unwarranted."  
Id. Unlike Professor Mwaria, Professor Duster does not propose to wholly abandon this 
genetic science at a potentially significant cost to human health. 
 
[FN15]. Consider that identification of a portfolio of genetic variations associated with 
breast cancer, including BRCA1, BRCA2, and Her2-neu, has made the corral of "breast 
cancer" genetically forced at best. 
 [FN16]. See generally John Carey, Medical Guesswork: From Heart Surgery to Prostate 
Care, The Health Industry Knows Little About Which Common Treatments Really Work, 
3989 Bus. Week 72 (2006). We want to think of medicine as a science, rather than an 
art, but, unfortunately, medicine is much, much cruder than we would like it to be--
especially when pharmaceuticals are involved. For decades, we have relied upon a 
portfolio of pharmaceuticals of 2,000-3,000, derived from less than 500 compounds, to 
treat all human health ailments. See Michael J. Malinowski, Law, Policy, and Market 
Implications of Genetic Profiling in Drug Development, 2 Hous. J. Health L. & Pol'y 31, 33 
n.10 (2002), citing Pharmaceutical Industry Profile 2001: A Century of Progress 14 
(2001). 
 
[FN17]. Pilar Ossorio, Race, Genetic Variation, and the Haplotype Mapping Project, 66 La. 
L. Rev. 131, 139 (2005). 
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